Multi-Modality Guidance System

  • Results of a cost-effectiveness analysis in the United States demonstrated a reduction in MI, revascularization, and cardiac death among general CAD population treated with IVUS as compared to angiography alone.1
  • IVUS was particularly effective in high risk subgroups, specifically in patients with diabetes, ACS, and Impaired Renal Function.2
  • Evidence suggests that IVUS reduces the rate of severe cardiac events at 30 days, which may result in fewer MI related readmissions. Thirty-day readmissions are measured under the US CMS readmissions reduction program.3
  • Over the lifetime of a CAD patient, IVUS could potentially save a total of $2,142 as compared to angiography alone.1
  • The potential savings are even higher ($2,997, $2,879, and $3,257) when modeling patients with diabetes, ACS, and impaired renal function.1

Adverse cardiac events are a substantial burden to the health system:

  • Cost per MI: $8,039*
  • Cost per revascularization: $12,948